Annovis Bio (ANVS)
(Delayed Data from NYSE)
$8.00 USD
-0.47 (-5.55%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $8.00 0.00 (0.00%) 6:48 PM ET
3-Hold of 5 3
D Value B Growth F Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ANVS 8.00 -0.47(-5.55%)
Will ANVS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ANVS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANVS
Amicus (FOLD) Up as Q2 Earnings & Sales Top, '24 View Updated
Xenon (XENE) Q2 Earnings Miss, Pipeline in Focus, Stock Down
ANVS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Intra-Cellular (ITCI) Q2 Loss Narrower Than Expected, Sales Beat
Catalyst (CPRX) Rises as Q2 Earnings & Revenues Beat Estimates
Editas (EDIT) Q2 Earnings & Revenues Miss Estimates, Stock Down
Other News for ANVS
Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference
Buy Rating on Annovis Bio Amid Progress in PD and AD Drug Development
ANVS Stock Earnings: Annovis Bio Beats EPS for Q2 2024
Annovis Bio (ANVS) Receives a Hold from Maxim Group
Largest borrow rate increases among liquid names